ERBB2 and breast cancer: Huang et al. have affirmed that the amplified expression of IL‐25R is linked to breast tumorigenesis and may serve as a better prognostic marker compared to HER2 amplification so that IL‐25R expression correlates to poor prognosis compared to HER2+ breast cancer.